Comparative Evaluation of In Vitro Drug Release Methods Employed for Nanoparticle Drug Release Studies

被引:11
作者
Paswan, Suresh K. [1 ]
Saini, T. R. [1 ]
机构
[1] Shri GS Inst Technol & Sci, Dept Pharm, Ind Pharm Res Lab, Indore, India
来源
DISSOLUTION TECHNOLOGIES | 2021年 / 28卷 / 04期
关键词
Nanoparticles; in vitro release methods; low-pressure ultrafiltration; dialysis bag; direct addition method; dissolution; SOLID LIPID NANOPARTICLES; LOADED PLGA NANOPARTICLES; DELIVERY; PACLITAXEL; ULTRAFILTRATION; FORMULATION; CARRIERS; BIOAVAILABILITY; NANOTECHNOLOGY; NANOMATERIALS;
D O I
10.14227/DT280421P30
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of the present study was to experimentally compare the attributes, drawbacks, and limitations of the most commonly employed in vitro drug release test methods for nanoparticle systems and to explore the possibility of one method being adopted as a standard for quality control of nanoparticle-based products. Three in vitro drug release test methods, i.e., direct addition, dialysis bag, and low-pressure ultrafiltration, were employed for evaluation of drug release from tamoxifen-loaded poly(lactic-co-glycolic acid) nanoparticles. Relevant operational characteristics of each test method were compared. Drug release data were fitted in different release kinetics models, i.e., zero order, first order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas. The coefficient of determination (R2), release rate constant (k), and release exponent (n) values were calculated. The direct addition method showed rapid initial drug release, whereas a slow release rate was observed in the dialysis bag method. Results of the low-pressure ultrafiltration method were consistent with the direct addition method and various operational characteristics were more realistic than the other two methods. Overall, the findings support that low-pressure ultrafiltration can be considered as a standard regulatory test method for in vitro release of nanoparticle-based formulations.
引用
收藏
页码:30 / 38
页数:9
相关论文
共 49 条
[1]  
[Anonymous], LA395 DIALYSIS MEMBR
[2]   Applications of nanoparticles for diagnosis and therapy of cancer [J].
Baetke, S. C. ;
Lammers, T. ;
Kiessling, F. .
BRITISH JOURNAL OF RADIOLOGY, 2015, 88 (1054)
[3]  
Bahman Fatemah, 2019, Pharmaceutical Nanotechnology, V7, P113, DOI 10.2174/2211738507666190321110721
[4]   Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposomes [J].
Bi, Ye ;
Zhou, Yulin ;
Wang, Mengqiao ;
Li, Lianlian ;
Lee, Robert J. ;
Xie, Jing ;
Teng, Lesheng .
ANTICANCER RESEARCH, 2017, 37 (09) :5207-5214
[5]   Characterisation of drug release from cubosomes using the pressure ultrafiltration method [J].
Boyd, BJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) :239-247
[6]   Formulation and In vitro Characterization of Eudragit® L100 and Eudragit® L100-PLGA Nanoparticles Containing Diclofenac Sodium [J].
Cetin, Meltem ;
Atila, Alptug ;
Kadioglu, Yucel .
AAPS PHARMSCITECH, 2010, 11 (03) :1250-1256
[7]  
Chidambaram N, 1999, AAPS PHARMSCI, V1
[8]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[9]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450
[10]   Freeze-drying of liposomes using tertiary butyl alcohol/water cosolvent systems [J].
Cui, JX ;
Li, CL ;
Deng, YJ ;
Wang, YL ;
Wang, W .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 312 (1-2) :131-136